Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Market Analysis
Generics erosion will lead to slow market growth for chronic heart failure treatment
February 27th, 2006
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, has found generics erosion, particularly for best-selling beta blockers and angiotensin-converting enzyme inhibitors, will result in slow market growth for the treatment of chronic heart failure. The new Pharmacor report entitled "Chronic Heart Failure" finds that recent guidelines recommending more widespread use of beta blockers should spur near-term increased sales of carvedilol, GlaxoSmithKline's Coreg and Roche's Dilatrend, as well as metoprolol succinate, AstraZeneca's Toprol XL. However, overall market growth will be offset by patent...
Source: Pharma Business Week (2006-02-27)
|
